WHO In Talks With Russian Institute On Sputnik V COVID-19 Vaccine

Daniel Fowler
November 16, 2020

Earlier this October, Dr Reddy's and Russia Direct Investment Fund (RDIF) received approval from the Drugs Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India.

RB Kamal, principal of Ganesh Shankar Vidyarthi Medical College, confirmed the clinical trials will start from next week. "The head of the research, Saurabh Agarwal, will determine the dosage of the vaccine to be administered".

Asked how many vaccines Britain would need, he said it depended on how effective they were at preventing transmission.

"A total of 40,000 volunteers are taking part in double-blind, randomized, placebo-controlled phase 3 clinical trials in Russian Federation", the RDIF said. He told that after applying the vaccine once or twice, its effect will be studied for seven months.

The Ethics Committee of the college has also given permission for the test.

Ontario close to canceling non-essential surgeries again as coronavirus cases spike
The majority of cases of COVID-19 since September have been among people under 60, but most deaths have been among the elderly. Caputo said the government has moved to supply facilities with personal protective equipment and additional staff support.

After observing the vaccine's effects for a month, authorities will be informed about the results of the trial and they can then make a decision accordingly. "More than 20,000 participants have been vaccinated with the first dose of the Sputnik V vaccine, and over 16,000 have received both the first and second doses of the vaccine".

South Korean bio company GL Rapha will produce over 150 million annual doses of Russia's COVID-19 vaccine for global distribution, Russia's sovereign wealth fund said Friday.

"The vaccine supplies to the global market will be produced by RDIF's worldwide partners in Korea, India, Brazil, China, and other countries", the Moscow-based fund said.

"The parties intend to commence production in December 2020 and a rollout of the Sputnik V vaccine in January 2021", the RDIF said in a press release posted on a website.

Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population.

Other reports by

Discuss This Article